Ingenia Therapeutics to self-fund first human study of glaucoma drug
AI Summary- Ingenia Therapeutics will develop its experimental glaucoma drug without a partner.
- Ingenia will fund the program's first human study from its own balance sheet.
- Merck's MSD unit declined to exercise its licensing option on the program.